Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.
Name:
Onco15852-233744-7-PB.pdf
Size:
6.610Mb
Format:
PDF
Description:
Full text, Open Access Article
Affiliation
The Paterson Institute, University of Manchester, Withington, M20 4BX, United KingdomIssue Date
2017-03-20
Metadata
Show full item recordCitation
Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer. 2017, OncotargetJournal
OncotargetDOI
10.18632/oncotarget.15852Additional Links
http://www.oncotarget.com/abstract/15852Type
ArticleISSN
1949-2553ae974a485f413a2113503eed53cd6c53
10.18632/oncotarget.15852